Boston Scientific Corporation (NYSE:BSX) agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy ...

Patients with cutaneous lupus erythematosus (CLE), an autoimmune disease that causes skin inflammation, have a higher risk ...

Bolt IVL platform uses acoustic waves to treat calcified artery lesions ... of potential treatments. Lithotripsy is a procedure in which a physician breaks up hardened masses such as calcium ...

Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based ...

IVL has gained attention in recent years as a more precise, efficient, and effective treatment for tough arterial calcium.

Mild chronic small vessel disease, or cerebral small vessel disease (CSVD), is an umbrella term for a range of conditions ...

The acquisition expands Boston Scientific's cardiovascular portfolio with Bolt's intravascular lithotripsy system.

Lithotripsy is a procedure in which a physician breaks up hardened masses such as ... systems for the treatment of peripheral artery disease in patients with moderate to severely calcified lesions.

Results showed that systemic lupus carries the greatest risk for heart health, more than doubling a person’s risk of heart disease compared to the healthy control group. But cutaneous lupus also ...

Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company's strategy to address coronary ...